Table 2. Open in new tab First‐line...

Table 2.

First‐line treatment outcomes in a cohort of GEA patients treated with second‐line FOLFIRI + ram

Treatment feature	n = 29, n (%)
First‐line therapy
FOLFOX/XELOX backbone	23 (79.3)
FOLFOX + trastuzumab	2 (6.8)
FOLFOX + experimental agent (trial)	12 (41.3)
Other 5FU + platinum	6 (20.7)
5FU + platinum‐containing triplets	6 (20.7)
FLOT	3 (10.3)
DOF	1 (3.4)
Modified DCF	1 (3.4)
ECX + placebo/experimental agent (trial)	1 (3.4)
Duration of 1L therapy, median (range), mo	7 (2–12)
Objective response to 1L
Complete response	1 (3.4)
Partial response	13 (44.8)
Stable disease	10 (34.4)
Progressive disease	3 (10.3)
Unknown or nonmeasurable	2 (6.9)
Maximal neuropathy grade
0	6 (20.7)
1	12 (41.4)
2	11 (37.9)

Treatment feature	n = 29, n (%)
First‐line therapy
FOLFOX/XELOX backbone	23 (79.3)
FOLFOX + trastuzumab	2 (6.8)
FOLFOX + experimental agent (trial)	12 (41.3)
Other 5FU + platinum	6 (20.7)
5FU + platinum‐containing triplets	6 (20.7)
FLOT	3 (10.3)
DOF	1 (3.4)
Modified DCF	1 (3.4)
ECX + placebo/experimental agent (trial)	1 (3.4)
Duration of 1L therapy, median (range), mo	7 (2–12)
Objective response to 1L
Complete response	1 (3.4)
Partial response	13 (44.8)
Stable disease	10 (34.4)
Progressive disease	3 (10.3)
Unknown or nonmeasurable	2 (6.9)
Maximal neuropathy grade
0	6 (20.7)
1	12 (41.4)
2	11 (37.9)

Denotes participation in a first line clinical trial. Total 45% (13/29) patients were treated on a first line clinical trial

Abbreviations: 1L, first‐line; 5FU, fluoropyrimidine; DCF, docetaxel, cisplatin, 5‐fluorouracil; DOF, docetaxel, oxaliplatin, 5‐fluorouracil; ECX, epirubicin, cisplatin, and capecitabine.

This Feature Is Available To Subscribers Only